Merck & Company, Inc. (MRK) to acquire SpringWorks Therapeutics, Inc. (SWTX) for $47/share in cash, creating synergies for ...

Merck KGaA’s $3.9 billion deal to buy SpringWorks Therapeutics Inc. will expand the German conglomerate’s presence in the US ...

German pharma company Merck is buying US biotech SpringWorks Therapeutics for $3.9B. SpringWorks makes medicines for cancer ...

The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.

Find insight on Merck KGaA, ResMed and more in the latest Market Talks covering the Health Care sector.

German science and technology giant Merck announced on Monday that it is to acquire US biopharmaceutical outfit SpringWorks Therapeutics as it attempts to ramp up growth in the healthcare sector.

Merck KGaA’s long courtship of SpringWorks Therapeutics has come to fruition as the German drugmaker has bought out the ...

Merck KGaA, Darmstadt, Germany, a science and technology company, has entered into a definitive agreement to acquire ...

Merck has entered into a definitive agreement to acquire SpringWorks Therapeutics for approximately $3.9 billion. This acquisition will significa ...

The Ademi Firm is investigating SpringWorks (Nasdaq: SWTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Merck. Click here to learn how to join our ...

Online retailer Temu — owned by PDD Holdings (PDD) — aims to raise prices amid tariffs, while Tesla (TSLA) raises its EV ...